18 July 2016
Roche has announced that the phase III GOYA study that evaluates Gazyva®/Gazyvaro® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint to significantly reduce the risk of disease worsening or death compared to MabThera/Rituxan (rituximab) plus CHOP chemotherapy (R-CHOP). It was observed that adverse events with MabThera/Rituxan and Gazyva/Gazyvaro were consistent with those seen in previous clinical trials when each was combined with various chemotherapies. At an upcoming medical meeting, data from the GOYA study will be presented.
Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development, said: “Two previous studies showed Gazyva/Gazyvaro helped people with previously untreated follicular lymphoma or chronic lymphocytic leukaemia live longer without their disease worsening compared to MabThera/Rituxan, when each was combined with chemotherapy. We were hopeful we could show a similar result for people with diffuse large B-cell lymphoma and once again improve on the standard of care. We will continue to analyze the GOYA data to better understand the results, and to study other investigational treatments in this disease with the goal of further helping these patients.”
Roche updates on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma last edit: 2016-07-25T17:29:52+00:00 da